There are 2789 resources available
1210P - Preclinical and preliminary clinical investigations of furmonertinib in NSCLC with EGFR exon 20 insertions (20ins)
Presenter: Baohui Han
Session: ePoster Display
1211P - Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion
Presenter: Sai-Hong Ou
Session: ePoster Display
1212P - Afatinib for the treatment of NSCLC with uncommon EGFR mutations: An updated database of 1023 cases
Presenter: James Yang Yang
Session: ePoster Display
1213P - Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in a real-life setting (CLEAR)
Presenter: Rami Nassabein
Session: ePoster Display
1214P - High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from a phase II multicenter study, POSITION20
Presenter: Fenneke Zwierenga
Session: ePoster Display
1215P - EGFR-mutated squamous cell lung cancer and its association with outcomes
Presenter: Yang Xia
Session: ePoster Display
1216P - Effectiveness of osimertinib plus chemotherapy and avastin for EGFR-mutated advanced non-small cell lung cancer with brain metastases
Presenter: Haifeng Qin
Session: ePoster Display
1217P - EGFR TKIs in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG)
Presenter: Satoru Miura
Session: ePoster Display
1219P - Study of anlotinib combined with icotinib as the first-line treatment in NSCLC patients harboring activating EGFR mutations: Updated results of ALTER-L004
Presenter: Dingzhi Huang
Session: ePoster Display